# Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

> **NCT01276041** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 70 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pertuzumab in combination with trastuzumab and paclitaxel

## Key facts

- **NCT ID:** NCT01276041
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-05
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276041, "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01276041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*